All Stories

  1. Diclofenac in the treatment of osteoarthritis
  2. Pooled safety analysis of diclofenac sodium topical solution 1.5% (w/w) in the treatment of osteoarthritis in patients aged 75 years or older
  3. Coming to Terms with Nonsteroidal Anti-Inflammatory Drug Gastropathy
  4. Diclofenac Sodium Topical Solution 1.5% w/w with Dimethyl Sulfoxide Compared with Placebo for the Treatment of Osteoarthritis: Pooled Safety Results
  5. Letter to the Editor: The Importance of Differentiating between Topical NSAIDs
  6. The NSAID Dilemma: Managing Osteoarthritis in High-Risk Patients
  7. Diclofenac sodium topical solution with dimethyl sulfoxide, a viable alternative to oral nonsteroidal anti-inflammatories in osteoarthritis: review of current evidence
  8. Diclofenac topical solution compared with oral diclofenac: a pooled safety analysis
  9. Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety
  10. Role of Apheresis in Rheumatoid Arthritis
  11. Understanding the COX-2/NSAID Dilemma
  12. Avoiding All Nonsteroidal Antiinflammatory Drug Toxicity
  13. Efficacy and Safety of a Topical Diclofenac Solution (Pennsaid) in the Treatment of Primary Osteoarthritis of the Knee
  14. Frank Dudley Hart
  15. Nabumetone
  16. Anticipating Rather Than Confirming Drug Toxicity Through Selective Laboratory Testing.
  17. Efficacy and Safety of a Once-Daily Morphine Formulation in Chronic, Moderate-to-Severe Osteoarthritis Pain
  18. Etoricoxib
  19. A New Role for Opioids in the Treatment of Arthritis
  20. Finessing Fibromyalgia
  21. Tramadol for the treatment of joint pain associated with osteoarthritis: a randomized, double-blind, placebo-controlled trial
  22. Nabumetone is associated with fewer endoscopic ulcers and fewer bleeding lesions than oxaprozin in elderly patients with osteoarthritis
  23. Around-the-Clock, Controlled-Release Oxycodone Therapy for Osteoarthritis-Related Pain
  24. Modalit??s d??utilisation de la nabum??tone et exp??rience clinique
  25. The prosorba column for treatment of refractory rheumatoid arthritis: A randomized, double-blind, sham-controlled trial
  26. Whose Pain Is It Anyhow?
  27. An examination of individual differences in the relationship between interpersonal stress and disease activity among women with rheumatoid arthritis
  28. NSAID Gastropathy-Reply
  29. Will Newer NSAIDs Relieve Pain Without Causing Life-Threatening Complications?
  30. NSAID Gastropathy
  31. Tenidap
  32. Long-term treatment with every-other-w eek methotrexate in rheumatoid arthritis patients with sustained disease improvement: Comment on the article by kremer et al
  33. From Peptic Ulcer Disease to NSAID Gastropathy
  34. Endoscopic Evaluation of the Long Term Effects of Diclofenac Sodium and Naproxen in Elderly Patients with Arthritis
  35. Interpersonal stress, depression, and disease activity in rheumatoid arthritis and osteoarthritis patients.
  36. A Controlled Study Comparing the Effects of Nabumetone, Ibuprofen, and Ibuprofen Plus Misoprostol on the Upper Gastrointestinal Tract Mucosa
  37. What role rheumatology?
  38. The Cost-effectiveness of Misoprostol
  39. Cost/Benefit Medicine, Red Flags, and Fibrositic Workscales
  40. Life stress and lymphocyte alterations among patients with rheumatoid arthritis.
  41. drugs for rheumatic disease. Harold Paulus, Daniel Furst, and Sydney Dromgoole, editors. New York, Churchill Livingstone, 1987. 488 pages. Illustrated. Indexed. $75.00
  42. Nonsteroidal Anti-Inflammatory Drugs: Gastropathy, Deaths, and Medical Practice
  43. Salicylates Revisited
  44. Naproxen: Antirheumatic efficacy and safety in patients with pre-existing gastrointestinal disease
  45. Nonsteroidal Anti-inflammatory Drug Gastropathy
  46. Cimetidine Therapy in Nonsteroidal Anti-inflammatory Drug Gastropathy
  47. Endoscopy-controlled study of the safety of nabumetone compared with naproxen in arthritis therapy
  48. Sucralfate treatment of nonsteroidal anti-inflammatory drug-induced gastrointestinal symptoms and mucosal damage
  49. What Is New in Arthritis Therapy
  50. Evaluating the Antirheumatic Drugs
  51. Adverse drug reactions: Working toward more appropriate monitoring models
  52. Nonsteroidal Anti-inflammatory Drug Gastropathy
  53. Impact of specific therapy upon rheumatoid arthritis
  54. A multicenter study of hospitalization in rheumatoid arthritis. Frequency, medical-surgical admissions, and charges
  55. A multicenter study of annual health service utilization and costs in rheumatoid arthritis
  56. Guidelines on New Anti-Rheumatic Drugs
  57. Letters
  58. Special studies of diclofenac and safety: Gastrointestinal, renal, hepatic, and other consequences of therapy
  59. A Practical Handbook of Joint Fluid Analysis,
  60. Drug Development, Guidelines, and the Food and Drug Administration
  61. The New Look in Drugs
  62. From experiment to experience: Side effects of nonsteroidal anti-inflammatory drugs
  63. Treatment of Rheumatoid Arthritis
  64. Rheumatology-Reply
  65. Drug Use, the Package Insert, and the Practice of Medicine
  66. What Role Rheumatology?
  67. Clinics in Rheumatic Diseases: Anti-Rheumatic Drugs II (Volume 6, Number 3). Edited by E. S. Huskisson. Eastbourne, W. B. Saunders, 1980. 236 pages. Price: $10.
  68. An Open Trial of Naproxen in Rheumatoid Arthritis Patients with Significant Esophageal, Gastric, and Duodenal Lesions
  69. Upper gastrointestinal disease in rheumatoid arthritis